A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Phase 3 Completed 901 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.

Timeline

Start: 2006-09
Primary completion: 2008-02
Completion: 2008-02

Publications

Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	150 mg	Oral
Subject	Aliskiren	Small molecule	300 mg	Oral
Comparator	Ramipril	Small molecule	5 mg	Oral
Comparator	Ramipril	Small molecule	10 mg	Oral
Background	Amlodipine	Other / unclassified	5 mg	Oral
Background	Amlodipine	Other / unclassified	10 mg	Oral
Background	Hydrochlorothiazide	Unknown	12.5 mg	Oral
Background	Hydrochlorothiazide	Unknown	25 mg	Oral

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Summary

Timeline

Publications

Drugs

Indications